Woman reading the Dagens Industri newspaper

Press releases

Category
Year

Oncopeptides publishes Q2 report 2023 Regulatory

August 10, 2023
Stockholm – August 10, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today publishes the report for the second quarter 2023
Read more

Oncopeptides appoints Henrik Bergentoft as Chief Financial Officer Regulatory

August 9, 2023
Stockholm – August 9, 2023 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the Company has appointed Henrik Bergentoft as Chief Financial Officer, CFO. Henrik was most recently CFO at RaySearch Laboratories and brings 20+ years of experience from leading finance roles at both medical and non-medical, publicly listed organizations. He will assume his new position during the fourth quarter, replacing Holger Lembrér
Read more

Sofia Heigis appointed CEO of Oncopeptides AB (publ) Regulatory

August 7, 2023
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announced that CEO Monica Shaw will be departing the company and transition over to Sofia Heigis who will move from the CCO role to take on the CEO role
Read more

Invitation to presentation of the Q2 report 2023

August 3, 2023
STOCKHOLM – August 3 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, will publish the report for the first quarter 2023 at 08:00 CET on August 10. Investors, financial analysts, and media are invited to participate in a webcast and a following Q&A session on August 10 at 09:00 CET
Read more

Number of shares and votes in Oncopeptides Regulatory

July 31, 2023
STOCKHOLM — July 31, 2023 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the number of shares and votes in Oncopeptides has changed as a result of the company’s issue of 219,843 new class C shares in accordance with the shareholder program Board SHP 2023 adopted by the annual general meeting on May 25, 2023
Read more

Issue and re-purchase of class C shares for shareholder program Regulatory

June 28, 2023
STOCKHOLM — June 28, 2023 — The Board of Directors of Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) (“Oncopeptides”), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, has today resolved, by virtue of the authorisation by the Annual General Meeting held on 25 May 2023, to issue and immediately thereafter re-purchase a total of 219 843 class C shares. The shares are issued and re-purchased in accordance with the shareholder program which was adopted by the Annual General Meeting held on 25 May 2023 (“Board SHP 2023”)
Read more

Oncopeptides complete first sales of Pepaxti in Greece

June 19, 2023
STOCKHOLM – June 19, 2023 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announced its first named patient sales of its flagship drug Pepaxti in Greece. The sales were made possible through Oncopeptides’ partnership with Ariti S.A., a company specialized on medical and pharmaceutical supply in Greece
Read more

Holger Lembrér will leave his role as Chief Financial Officer at Oncopeptides Regulatory

June 14, 2023
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announced that Holger Lembrér, Chief Financial Officer (CFO) has decided to leave Oncopeptides to pursue a new role in another company. Holger was appointed CFO in January 2023. He will continue in his current role until December or until a new CFO takes office. A recruitment process will be initiated immediately
Read more

The Swedish Economic Crime Authority terminates the investigation of Oncopeptide’s Chief Scientific Officer Jakob Lindberg

May 30, 2023
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, has been informed that the preliminary investigation by the Swedish Economic Crime Authority of the company’s Chief Scientific Officer and former CEO has been terminated
Read more

Bulletin from the Annual General Meeting in Oncopeptides AB (publ) Regulatory

May 25, 2023
Stockholm, Sweden – The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Thursday, 25 May 2023. At the Annual General Meeting, the following principal resolutions were passed
Read more